Novavax Common Stock Shares Outstanding vs Total Current Liabilities Analysis
NVAX Stock | USD 9.11 0.09 1.00% |
Novavax financial indicator trend analysis is infinitely more than just investigating Novavax recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novavax is a good investment. Please check the relationship between Novavax Common Stock Shares Outstanding and its Total Current Liabilities accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.
Common Stock Shares Outstanding vs Total Current Liabilities
Common Stock Shares Outstanding vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novavax Common Stock Shares Outstanding account and Total Current Liabilities. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Novavax's Common Stock Shares Outstanding and Total Current Liabilities is 0.88. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Novavax, assuming nothing else is changed. The correlation between historical values of Novavax's Common Stock Shares Outstanding and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Novavax are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Common Stock Shares Outstanding i.e., Novavax's Common Stock Shares Outstanding and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | 0.88 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Total Current Liabilities
Total Current Liabilities is an item on Novavax balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Novavax are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Novavax's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novavax current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.At this time, Novavax's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 442.5 M in 2024, despite the fact that Tax Provision is likely to grow to (1.8 M).
Novavax fundamental ratios Correlations
Click cells to compare fundamentals
Novavax Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novavax fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 173.0M | 1.6B | 2.6B | 2.3B | 1.8B | 1.9B | |
Other Current Liab | 19.9M | (327.6M) | 709.8M | 1.5B | 1.3B | 1.3B | |
Total Current Liabilities | 25.8M | 322.0M | 2.4B | 2.5B | 1.6B | 1.7B | |
Total Stockholder Equity | (186.0M) | 627.2M | (351.7M) | (634.1M) | (716.9M) | (681.1M) | |
Property Plant And Equipment Net | 11.4M | 180.0M | 228.7M | 400.5M | 491.0M | 515.5M | |
Net Debt | 243.1M | (231.4M) | (1.1B) | (787.1M) | (339.4M) | (322.5M) | |
Retained Earnings | (1.4B) | (1.9B) | (3.6B) | (4.3B) | (4.8B) | (4.6B) | |
Accounts Payable | 2.9M | 54.3M | 127.1M | 216.5M | 132.6M | 139.2M | |
Cash | 78.8M | 553.4M | 1.5B | 1.3B | 568.5M | 596.9M | |
Non Current Assets Total | 75.7M | 334.3M | 421.6M | 555.3M | 711.5M | 747.0M | |
Non Currrent Assets Other | 7.5M | 13.2M | 56.7M | 28.5M | 88.1M | 92.5M | |
Cash And Short Term Investments | 78.8M | 711.0M | 1.5B | 1.3B | 568.5M | 596.9M | |
Common Stock Shares Outstanding | 24.1M | 57.6M | 74.4M | 78.2M | 100.8M | 105.8M | |
Liabilities And Stockholders Equity | 173.0M | 1.6B | 2.6B | 2.3B | 1.8B | 1.9B | |
Other Current Assets | 93.9M | 441.8M | 176.1M | 247.5M | 236.4M | 248.3M | |
Other Stockholder Equity | 1.3B | 2.5B | 3.3B | 3.6B | 4.1B | 4.3B | |
Total Liab | 359.0M | 955.3M | 2.9B | 2.9B | 2.5B | 2.6B | |
Property Plant And Equipment Gross | 11.4M | 180.0M | 258.6M | 447.8M | 566.0M | 594.3M | |
Total Current Assets | 97.2M | 1.2B | 2.2B | 1.7B | 1.1B | 1.2B | |
Accumulated Other Comprehensive Income | (12.5M) | 7.0M | (1.4M) | (6.4M) | 2.7M | 2.9M | |
Net Receivables | 7.5M | 262.0M | 455.0M | 82.4M | 297.2M | 312.1M | |
Non Current Liabilities Total | 333.2M | 633.2M | 538.1M | 432.8M | 937.1M | 984.0M | |
Intangible Assets | 6.5M | 5.6M | 5.7M | 4.8M | 4.3M | 4.1M | |
Short Long Term Debt Total | 321.9M | 322.0M | 454.0M | 549.8M | 229.1M | 140.8M | |
Common Stock Total Equity | 3.8M | 324K | 714K | 764K | 878.6K | 1.3M | |
Short Term Debt | 1.3M | 322.0M | 130.5M | 352.1M | 5.1M | 4.9M | |
Common Stock | 324K | 714K | 764K | 868K | 1.4M | 1.3M | |
Long Term Debt | 320.6M | 322.0M | 323.5M | 166.5M | 168.0M | 114.6M | |
Inventory | (83.0M) | (166.7M) | (2.0B) | 36.7M | 41.7M | 43.8M | |
Property Plant Equipment | 11.4M | 180.0M | 228.7M | 400.5M | 460.6M | 483.6M | |
Other Liab | 2.6M | 3.4M | 175.5M | 185.0M | 212.8M | 223.4M | |
Current Deferred Revenue | 1.7M | 273.2M | 1.4B | 370.1M | 241.3M | 140.2M | |
Other Assets | 1.1M | 5.4M | 16.6M | 28.5M | (57.9M) | (55.0M) | |
Good Will | 51.2M | 135.4M | 131.5M | 126.3M | 127.5M | 133.8M | |
Short Term Investments | 22.0M | 0.0 | 157.6M | 10.4M | 12.0M | 11.4M | |
Net Tangible Assets | (242.8M) | 486.1M | (487.9M) | (760.4M) | (684.4M) | (650.1M) | |
Retained Earnings Total Equity | (1.3B) | (1.4B) | (1.9B) | (3.6B) | (3.3B) | (3.1B) | |
Long Term Debt Total | 319.2M | 320.6M | 322.0M | 323.5M | 372.0M | 234.9M | |
Capital Surpluse | 1.1B | 1.3B | 2.5B | 3.4B | 3.9B | 4.0B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.